Study: J&J and Bayer's anticoagulant Xarelto yields mixed results

04/5/2011 | Reuters

A clinical study found that Bayer and Johnson & Johnson's anticoagulant Xarelto worked as well as standard injectable drug Lovenox, by Sanofi-Aventis, in preventing blood clots after 10 days of treatment among patients hospitalized for acute illnesses. However, the incidence of bleeding among Xarelto users after 35 days of treatment was more than double the rate seen in Lovenox users.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations